AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 157 filers reported holding AERIE PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $12,036,000 | +171.9% | 795,473 | +34.8% | 0.02% | +240.0% |
| Q2 2022 | $4,427,000 | -2.4% | 590,310 | +18.5% | 0.01% | 0.0% |
| Q1 2022 | $4,534,000 | +68.1% | 498,210 | +29.6% | 0.01% | +66.7% |
| Q4 2021 | $2,698,000 | -26.4% | 384,310 | +19.5% | 0.00% | -40.0% |
| Q3 2021 | $3,667,000 | -37.7% | 321,710 | -12.4% | 0.01% | -28.6% |
| Q2 2021 | $5,882,000 | +44.7% | 367,373 | +61.5% | 0.01% | +40.0% |
| Q1 2021 | $4,066,000 | +5.0% | 227,510 | -20.6% | 0.01% | +25.0% |
| Q4 2020 | $3,871,000 | +3.1% | 286,510 | -10.2% | 0.00% | 0.0% |
| Q3 2020 | $3,756,000 | -11.0% | 319,100 | +11.6% | 0.00% | 0.0% |
| Q2 2020 | $4,221,000 | +24.2% | 286,000 | +103.4% | 0.00% | +33.3% |
| Q4 2019 | $3,398,000 | +108.0% | 140,600 | +65.4% | 0.00% | +200.0% |
| Q3 2019 | $1,634,000 | -48.6% | 85,000 | -16.2% | 0.00% | -85.7% |
| Q1 2015 | $3,178,000 | – | 101,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 246,563 | $2,244,000 | 1.36% |
| LEVIN CAPITAL STRATEGIES, L.P. | 1,435,876 | $13,066,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,695,020 | $42,725,000 | 0.96% |
| DCF Advisers, LLC | 189,565 | $1,725,000 | 0.76% |
| DAFNA Capital Management LLC | 289,040 | $2,630,000 | 0.68% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,678,609 | $15,275,000 | 0.61% |
| Rhenman & Partners Asset Management AB | 589,200 | $5,362,000 | 0.53% |
| PFM Health Sciences, LP | 1,088,566 | $9,906,000 | 0.37% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 309,778 | $2,819,000 | 0.36% |
| Granahan Investment Management | 1,588,944 | $14,459,000 | 0.36% |